Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways
Authors
Keywords
-
Journal
CLINICAL SCIENCE
Volume 136, Issue 18, Pages 1347-1366
Publisher
Portland Press Ltd.
Online
2022-09-23
DOI
10.1042/cs20220572
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Fenofibrate Improves Insulin Resistance and Hepatic Steatosis and Regulates the Let-7/SERCA2b Axis in High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease Mice
- (2022) Dan Zhang et al. Frontiers in Pharmacology
- Reactive Oxygen Species (ROS) and Antioxidants as Immunomodulators in Exercise: Implications for Heme Oxygenase and Bilirubin
- (2022) David Travis Thomas et al. Antioxidants
- Hepatic kinome atlas: An in‐depth identification of kinase pathways in liver fibrosis of humans and rodents
- (2022) Justin F. Creeden et al. HEPATOLOGY
- Fecal Microbiota Transplant from Human to Mice Gives Insights into the Role of the Gut Microbiota in Non-Alcoholic Fatty Liver Disease (NAFLD)
- (2021) Sebastian D. Burz et al. Microorganisms
- THR‐ß agonism improves disease activity and metabolism independent of body weight in a mouse model of non‐alcoholic steatohepatitis and fibrosis
- (2021) Aimo Kannt et al. BRITISH JOURNAL OF PHARMACOLOGY
- Beneficial effects of elafibranor on NASH in E3L.CETP mice and differences between mice and men
- (2021) Anita M. van den Hoek et al. Scientific Reports
- Identification of Binding Regions of Bilirubin in the Ligand-Binding Pocket of the Peroxisome Proliferator-Activated Receptor-A (PPARalpha)
- (2021) Darren M. Gordon et al. MOLECULES
- Is insulin the preferred treatment in persons with type 2 diabetes and liver cirrhosis?
- (2021) Fu-Shun Yen et al. BMC GASTROENTEROLOGY
- Selective acetyl-CoA carboxylase 1 inhibitor improves hepatic steatosis and hepatic fibrosis in a pre-clinical NASH model
- (2021) Yumiko Okano Tamura et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- FKBP51 and the molecular chaperoning of metabolism
- (2021) Kathryn B. Smedlund et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Non-Alcoholic Steatohepatitis (NASH) – A Review of a Crowded Clinical Landscape, Driven by a Complex Disease
- (2021) Julia M Fraile et al. Drug Design Development and Therapy
- Metformin Alleviates Hepatic Steatosis and Insulin Resistance in a Mouse Model of High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease by Promoting Transcription Factor EB-Dependent Autophagy
- (2021) Dan Zhang et al. Frontiers in Pharmacology
- Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease
- (2021) Chander K. Negi et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials
- (2021) Roberto A. Calle et al. NATURE MEDICINE
- A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
- (2021) Sven M. Francque et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overexpression of PDE4D in mouse liver is sufficient to trigger NAFLD and hypertension in a CD36-TGF-β1 pathway: therapeutic role of roflumilast
- (2021) Xiang Tao et al. PHARMACOLOGICAL RESEARCH
- Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis
- (2021) Rasoul Akbari et al. BMC Pharmacology & Toxicology
- Adipose-Specific PPARα Knockout Mice Have Increased Lipogenesis by PASK–SREBP1 Signaling and a Polarity Shift to Inflammatory Macrophages in White Adipose Tissue
- (2021) Terry D. Hinds et al. Cells
- Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes
- (2020) Lin Liu et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease
- (2020) Mohammed Eslam et al. GASTROENTEROLOGY
- Biliverdin Reductase A (BVRA) Knockout in Adipocytes Induces Hypertrophy and Reduces Mitochondria in White Fat of Obese Mice
- (2020) David E. Stec et al. Biomolecules
- PPARs as Metabolic Regulators in the Liver: Lessons from Liver-Specific PPAR-Null Mice
- (2020) Yaping Wang et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Bilirubin remodels murine white adipose tissue by reshaping mitochondrial activity and the coregulator profile of peroxisome proliferator-activated receptor α
- (2020) Darren M Gordon et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
- (2020) Mohammed Eslam et al. JOURNAL OF HEPATOLOGY
- Protective effect of fenofibrate against high fat‐high fructose diet induced non‐obese NAFLD in rats
- (2020) Doaa Abdelmoneim et al. FUNDAMENTAL & CLINICAL PHARMACOLOGY
- Metabolic liver disease in diabetes – From mechanisms to clinical trials
- (2020) Bedair Dewidar et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease
- (2020) Divya P. Kumar et al. Scientific Reports
- Prevalence trends in non-alcoholic fatty liver disease at the global, regional and national levels, 1990–2017: a population-based observational study
- (2020) Xiaojun Ge et al. BMJ Open
- Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease
- (2020) Anne Fougerat et al. Cells
- Could SCGF-Beta Levels Be Associated with Inflammation Markers and Insulin Resistance in Male Patients Suffering from Obesity-Related NAFLD?
- (2020) Giovanni Tarantino et al. Diagnostics
- Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
- (2020) Hoda Taheri et al. ADVANCES IN THERAPY
- Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver?
- (2020) Patricia Rada et al. Cell Death & Disease
- Effect of Saxagliptin, a Dipeptidyl Peptidase 4 Inhibitor, on Non-Alcoholic Fatty Liver Disease
- (2020) Lin Chen et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Rats Genetically Selected for High Aerobic Exercise Capacity Have Elevated Plasma Bilirubin by Upregulation of Hepatic Biliverdin Reductase-A (BVRA) and Suppression of UGT1A1
- (2020) Terry D. Hinds et al. Antioxidants
- Bilirubin as a metabolic hormone: the physiological relevance of low levels
- (2020) Justin F. Creeden et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Natural Product Heme Oxygenase Inducers as Treatment for Nonalcoholic Fatty Liver Disease
- (2020) David E. Stec et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Regulation of gene transcription by thyroid hormone receptor β agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH)
- (2020) Xuan G. Luong et al. PLoS One
- Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study
- (2020) Omesh Goyal et al. Scientific Reports
- Bilirubin Nanoparticles Reduce Diet-Induced Hepatic Steatosis, Improve Fat Utilization, and Increase Plasma β-Hydroxybutyrate
- (2020) Terry D. Hinds et al. Frontiers in Pharmacology
- ChREBP-Mediated Regulation of Lipid Metabolism: Involvement of the Gut Microbiota, Liver, and Adipose Tissue
- (2020) Katsumi Iizuka et al. Frontiers in Endocrinology
- Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity
- (2019) Maria J. Pereira et al. DRUGS
- Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus
- (2019) Lee-Lee Lai et al. DIGESTIVE DISEASES AND SCIENCES
- RNA-sequencing in human HepG2 hepatocytes reveals PPARα mediates transcriptome responsiveness of bilirubin.
- (2019) Darren M Gordon et al. PHYSIOLOGICAL GENOMICS
- New dual peroxisome proliferator activated receptor agonist—Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence
- (2019) Upendra Kaul et al. Cardiovascular Diabetology
- The loss of hepatic PPARα promotes inflammation and serum hyperlipidemia in diet-induced obesity
- (2019) David E. Stec et al. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
- CRISPR Cas9-mediated deletion of biliverdin reductase A (BVRA) in mouse liver cells induces oxidative stress and lipid accumulation
- (2019) Darren M. Gordon et al. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
- Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study
- (2019) Nam Hoon Kim et al. BMJ-British Medical Journal
- Bilirubin Safeguards Cardiorenal and Metabolic Diseases: a Protective Role in Health
- (2019) Terry D. Hinds et al. CURRENT HYPERTENSION REPORTS
- Circulating total bilirubin and risk of non-alcoholic fatty liver disease in the PREVEND study: observational findings and a Mendelian randomization study
- (2019) Setor K. Kunutsor et al. EUROPEAN JOURNAL OF EPIDEMIOLOGY
- Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2019) Stephen A Harrison et al. LANCET
- Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults
- (2019) Myriam Alexander et al. BMJ-British Medical Journal
- Fenofibrate rapidly decreases hepatic lipid and glycogen storage in neonatal mice with glycogen storage disease type Ia
- (2019) Zollie A Yavarow et al. HUMAN MOLECULAR GENETICS
- Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease
- (2019) Gordon I. Smith et al. JOURNAL OF CLINICAL INVESTIGATION
- Evolution of NAFLD and Its Management
- (2019) Manpreet S. Mundi et al. NUTRITION IN CLINICAL PRACTICE
- Biliverdin reductase and bilirubin in hepatic disease
- (2018) Lauren Weaver et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease
- (2018) David Højland Ipsen et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes
- (2018) Fernando Bril et al. Clinical Gastroenterology and Hepatology
- Acetyl-CoA Carboxylase Inhibition Reverses NAFLD and Hepatic Insulin Resistance but Promotes Hypertriglyceridemia in Rodents
- (2018) Leigh Goedeke et al. HEPATOLOGY
- Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
- (2018) Hidenori Arai et al. Journal of Atherosclerosis and Thrombosis
- Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?
- (2018) Amedeo Lonardo et al. JOURNAL OF HEPATOLOGY
- Mechanisms of NAFLD development and therapeutic strategies
- (2018) Scott L. Friedman et al. NATURE MEDICINE
- Bilirubin in the Liver–Gut Signaling Axis
- (2018) Abdul-Rizaq Hamoud et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis
- (2018) Kirstine S Tølbøl et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Exenatide Delays the Progression of Nonalcoholic Fatty Liver Disease in C57BL/6 Mice, Which May Involve Inhibition of the NLRP3 Inflammasome through the Mitophagy Pathway
- (2018) Ning Shao et al. Gastroenterology Research and Practice
- Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH
- (2018) Kumiko Shiba et al. Scientific Reports
- Bilirubin, a new therapeutic for kidney transplant?
- (2018) Vikram L. Sundararaghavan et al. Transplantation Reviews
- Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial
- (2018) Naveed Sattar et al. DIABETOLOGIA
- Bilirubin, a Cardiometabolic Signaling Molecule
- (2018) Terry D. Hinds et al. HYPERTENSION
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
- (2018) DIABETES CARE
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
- (2017) Naga Chalasani et al. HEPATOLOGY
- Current and future pharmacological therapies for NAFLD/NASH
- (2017) Yoshio Sumida et al. JOURNAL OF GASTROENTEROLOGY
- Fenofibrate, but not ezetimibe, prevents fatty liver disease in mice lacking phosphatidylethanolamineN-methyltransferase
- (2017) Jelske N. van der Veen et al. JOURNAL OF LIPID RESEARCH
- PPARα protects against trans -fatty-acid-containing diet-induced steatohepatitis
- (2017) Xiao Hu et al. JOURNAL OF NUTRITIONAL BIOCHEMISTRY
- Dietary intervention, but not losartan, completely reverses non-alcoholic steatohepatitis in obese and insulin resistant mice
- (2017) Jef Verbeek et al. Lipids in Health and Disease
- Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial
- (2017) Tisha R Joy et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Deciphering the Roles of Thiazolidinediones and PPARγ in Bladder Cancer
- (2017) Melody Chiu et al. PPAR Research
- Silencing of FABP1 ameliorates hepatic steatosis, inflammation, and oxidative stress in mice with nonalcoholic fatty liver disease
- (2017) Takako Mukai et al. FEBS Open Bio
- The glucocorticoid receptor: cause of or cure for obesity?
- (2016) Kezia John et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Effect of canagliflozin on liver function tests in patients with type 2 diabetes
- (2016) L.A. Leiter et al. DIABETES & METABOLISM
- Serum β-trophin level as a new marker for noninvasive assessment of nonalcoholic fatty liver disease and liver fibrosis
- (2016) Mustafa Cengiz et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
- (2016) Vlad Ratziu et al. GASTROENTEROLOGY
- Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD
- (2016) Alexandra Montagner et al. GUT
- Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes
- (2016) Zobair M. Younossi et al. HEPATOLOGY
- Biliverdin Reductase A Attenuates Hepatic Steatosis by Inhibition of Glycogen Synthase Kinase (GSK) 3β Phosphorylation of Serine 73 of Peroxisome Proliferator-activated Receptor (PPAR) α
- (2016) Terry D. Hinds et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Glucocorticoid Receptor β Induces Hepatic Steatosis by Augmenting Inflammation and Inhibition of the Peroxisome Proliferator-activated Receptor (PPAR) α
- (2016) Joseph S. Marino et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Does bilirubin prevent hepatic steatosis through activation of the PPARα nuclear receptor?
- (2016) Terry D. Hinds et al. MEDICAL HYPOTHESES
- Prediction of Nonalcoholic Fatty Liver Disease Via a Novel Panel of Serum Adipokines
- (2016) Raika Jamali et al. MEDICINE
- Deregulated Lipid Sensing by Intestinal CD36 in Diet-Induced Hyperinsulinemic Obese Mouse Model
- (2016) Marjorie Buttet et al. PLoS One
- Timcodar (VX-853) Is a Non-FKBP12 Binding Macrolide Derivative That Inhibits PPARγand Suppresses Adipogenesis
- (2016) Terry D. Hinds et al. PPAR Research
- Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes
- (2016) Teruo Jojima et al. Diabetology & Metabolic Syndrome
- Glucuronidation and UGT isozymes in bladder: new targets for the treatment of uroepithelial carcinomas?
- (2016) Vikram L. Sundararaghavan et al. Oncotarget
- Thyroid hormone-mediated autophagy and mitochondrial turnover in NAFLD
- (2016) Rohit Anthony Sinha et al. Cell and Bioscience
- Bilirubin Binding to PPARα Inhibits Lipid Accumulation
- (2016) David E. Stec et al. PLoS One
- Features of an altered AMPK metabolic pathway in Gilbert’s Syndrome, and its role in metabolic health
- (2016) Christine Mölzer et al. Scientific Reports
- Fatty acid transport protein-2 inhibitor Grassofermata/CB5 protects cells against lipid accumulation and toxicity
- (2015) Nipun Saini et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- De novolipogenesis in the liver in health and disease: more than just a shunting yard for glucose
- (2015) Francis W. B. Sanders et al. BIOLOGICAL REVIEWS
- PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis
- (2015) Sven Francque et al. JOURNAL OF HEPATOLOGY
- Recent insights into the biological functions of liver fatty acid binding protein 1
- (2015) GuQi Wang et al. JOURNAL OF LIPID RESEARCH
- Biliverdin reductase isozymes in metabolism
- (2015) Luke O’Brien et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Rapamycin-mediated CD36 translational suppression contributes to alleviation of hepatic steatosis
- (2014) Chuan Wang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Metformin Ameliorates Hepatic Steatosis and Inflammation without Altering Adipose Phenotype in Diet-Induced Obesity
- (2014) Shih-Lung Woo et al. PLoS One
- 17β-estradiol inhibits PPARα of skeletal muscle
- (2013) Hyunghee Lee et al. Animal Cells and Systems
- Dual Peroxisome Proliferator-Activated Receptor / Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects
- (2013) B. Cariou et al. DIABETES CARE
- Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice
- (2013) Atsuo Tahara et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Unconjugated bilirubin, a potent endogenous antioxidant, is decreased in patients with non-alcoholic steatohepatitis and advanced fibrosis
- (2013) Federico Salomone et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Serum Bilirubin Level Is Inversely Associated With Nonalcoholic Steatohepatitis in Children
- (2013) Kanika Puri et al. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
- MTTPpolymorphisms and susceptibility to non-alcoholic fatty liver disease in a Han Chinese population
- (2013) Xian E. Peng et al. LIVER INTERNATIONAL
- Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY)
- (2013) Takumi Hirata et al. International Journal of Endocrinology
- Unconjugated hyperbilirubinemia is inversely associated with non-alcoholic steatohepatitis (NASH)
- (2012) M. Hjelkrem et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- MRI Steatosis Grading: Development and Initial Validation of a Color Mapping System
- (2012) Aliya Qayyum et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- Vitamin E and nonalcoholic fatty liver disease
- (2012) Tommy Pacana et al. CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE
- Metformin-Induced Hepatotoxicity
- (2012) F. Miralles-Linares et al. DIABETES CARE
- Effect of valsartan on the pathological progression of hepatic fibrosis in rats with type 2 diabetes
- (2012) Guifen Qiang et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Beneficial effects of candesartan, an angiotensin-blocking agent, on compensated alcoholic liver fibrosis - A randomized open-label controlled study
- (2012) Moon Young Kim et al. LIVER INTERNATIONAL
- Liver-Specific Expression of Transcriptionally Active SREBP-1c Is Associated with Fatty Liver and Increased Visceral Fat Mass
- (2012) Birgit Knebel et al. PLoS One
- PPARα activation differently affects microparticle content in atherosclerotic lesions and liver of a mouse model of atherosclerosis and NASH
- (2011) Morgane Baron et al. ATHEROSCLEROSIS
- Diet-Induced Adipose Tissue Inflammation and Liver Steatosis Are Prevented by DPP-4 Inhibition in Diabetic Mice
- (2011) J. Shirakawa et al. DIABETES
- Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C
- (2011) M. E. Miquilena-Colina et al. GUT
- Inverse Association Between Total Bilirubin and Metabolic Syndrome in Rural Korean Women
- (2011) Kyung-Min Kwon et al. JOURNAL OF WOMENS HEALTH
- Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis
- (2011) Gianluca Svegliati-Baroni et al. LIVER INTERNATIONAL
- Low serum total bilirubin concentrations are associated with increased prevalence of metabolic syndrome in Chinese
- (2011) Yaohua WU et al. Journal of Diabetes
- Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis
- (2010) M. O. Rakoski et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Exenatide in the Treatment of Diabetic Patients With Non-Alcoholic Steatohepatitis: A Case Series
- (2010) Patrick R Kenny et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Hepatotoxicity Associated with Metformin Therapy in Treatment of Type 2 Diabetes Mellitus with Nonalcoholic Fatty Liver Disease
- (2010) Catherine J Cone et al. ANNALS OF PHARMACOTHERAPY
- Epidemiology of Non-Alcoholic Fatty Liver Disease
- (2010) Stefano Bellentani et al. DIGESTIVE DISEASES
- A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease
- (2010) Giovanni Musso et al. HEPATOLOGY
- A Promoter Polymorphism in the Liver-specific Fatty Acid Transport Protein 5 is Associated with Features of the Metabolic Syndrome and Steatosis
- (2010) A. Auinger et al. HORMONE AND METABOLIC RESEARCH
- Involvement of microsomal triglyceride transfer protein in nonalcoholic steatohepatitis in novel spontaneous mouse model
- (2010) Nobuyasu Shindo et al. JOURNAL OF HEPATOLOGY
- High Serum Bilirubin Is Associated with the Reduced Risk of Diabetes Mellitus and Diabetic Nephropathy
- (2010) Seung Seok Han et al. TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
- PPARαin Obesity: Sex Difference and Estrogen Involvement
- (2010) Michung Yoon PPAR Research
- Long-term Administration of Rapamycin Reduces Adiposity, but Impairs Glucose Tolerance in High-Fat Diet-fed KK/HlJ Mice
- (2009) Geng-Ruei Chang et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin
- (2009) Manuel Romero-Gómez et al. HEPATOLOGY
- Variants in the UGT1A1 Gene and the Risk of Pediatric Nonalcoholic Fatty Liver Disease
- (2009) Y.-C. Lin et al. PEDIATRICS
- The role of PPARα in lipid metabolism and obesity: Focusing on the effects of estrogen on PPARα actions
- (2009) Michung Yoon PHARMACOLOGICAL RESEARCH
- Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels
- (2008) V. W.-S. WONG et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Selective versus Total Insulin Resistance: A Pathogenic Paradox
- (2008) Michael S. Brown et al. Cell Metabolism
- Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
- (2008) R. Scott et al. DIABETES CARE
- Silencing of Hepatic Fatty Acid Transporter Protein 5in VivoReverses Diet-induced Non-alcoholic Fatty Liver Disease and Improves Hyperglycemia
- (2008) Holger Doege et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Inhibition of apolipoprotein B100 secretion by lipid-induced hepatic endoplasmic reticulum stress in rodents
- (2008) Tsuguhito Ota et al. JOURNAL OF CLINICAL INVESTIGATION
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started